Sugi Predict

Sugi Predict / Compounds / SCHEMBL415949

SCHEMBL415949

SCHEMBL415949

Clc1ccc(CNCc2ccc(Cl)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.67
▸ ALDH1A1 P00352 1/20 0.65
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ GAA P10253 1/20 0.53
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ IDO1 P14902 1/20 0.50
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA4 P22748 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ OXTR P30559 1/20 0.47
▸ AVPR1A P37288 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7695180 0.97 CHRM2 (0.64) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL9479829 0.95 CHRM2 (0.61) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL606264 0.90 ALDH1A1 (0.62) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL11094422 0.89 CHRM2 (0.75) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL7250935 0.88 CHRM2 (0.55) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL16180798 0.88 ALDH1A1 (0.60) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL8493136 0.88 ALDH1A1 (0.60) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4574058 0.86 CHRM2 (0.53) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL23901557 0.85 CHRM2 (0.57) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL6342311 0.85 CHRM2 (0.57) CHRM2ALDH1A1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513260-B2 Pyrazinylpyrazoles BAYER CROPSCIENCE AG (DE) 2013-08-20 — — US claimed
EP-2435420-B1 Pyrazinylpyrazoles BAYER CROPSCIENCE AG (DE) 2013-04-03 — — EP claimed
US-20120190687-A1 Pyrazinylpyrazoles BAYER CROPSCIENCE AG 2012-07-26 — — US claimed
US-20110021539-A1 Pyrazinylpyrazoles BAYER CROPSCIENCE AG (DE) 2011-01-27 — — US claimed
WO-2010136145-A1 PYRAZINYLPYRAZOLES BAYER CROPSCIENCE AG (DE) 2010-12-02 — — WO claimed
CN-122028918-A TRIM7 inhibitors and uses thereof 沙塔克实验室有限公司 2026-05-12 — — CN disclosed
WO-2025042798-A1 TRIM7 INHIBITORS AND USES THEREOF SHATTUCK LABS, INC. (US) 2025-02-27 — — WO disclosed
CN-118878835-A Free radical crystalline porous organic salt, preparation method thereof and photocatalysis application 江苏师范大学 2024-11-01 — — CN disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 — — US disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 — — US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 — — WO disclosed
US-20190210992-A1 AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS TEXAS HEART INSTITUTE (US) 2019-07-11 — — US disclosed
US-20030144526-A1 Calcium receptor-active compounds NPS PHARMACEUTICALS, INC. 2003-07-31 — — US disclosed
EP-1155001-A4 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES LION BIOSCIENCE AG (DE) 2003-05-28 — — EP disclosed
US-20020107406-A1 Calcium receptor-active compounds NPS PHARMACEUTICALS, INC. (US) 2002-08-08 — — US disclosed
US-6362231-B1 MODULATOR OF PARATHYROID HORMONE; OSTEOPOROSIS NPS PHARMACEUTICALS, INC. 2002-03-26 — — US disclosed
EP-1155001-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES TREGA BIOSCIENCES, INC. (US) 2001-11-21 — — EP disclosed
WO-2000050406-A1 ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES LION BIOSCIENCE AG (DE) 2000-08-31 — — WO disclosed
EP-0933354-A1 CALCIUM RECEPTOR-ACTIVE COMPOUNDS KIRIN BEER KABUSHIKI KAISHA (JP) 1999-08-04 — — EP disclosed
US-4413045-A Multilayer electrophotographic photosensitive member comprises disazo charge generator layer, hydrazone transport layer CANON KABUSHIKI KAISHA (JP) 1983-11-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144526-A1 Calcium receptor-active compounds CASR, CALCR, CNR1 CHRM2 604/4885ALDH1A1 3470/4885SMN1; SMN2 3860/4885
US-20110021539-A1 Pyrazinylpyrazoles CYP4F3, CYP4B1, CYP1A2 CHRM2 2048/4885ALDH1A1 2140/4885SMN1; SMN2 2333/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT CHRM2 3040/4885ALDH1A1 481/4885SMN1; SMN2 2118/4885
US-20190210992-A1 AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS ITGB7, ITGAL, ITGB1 CHRM2 326/4885ALDH1A1 725/4885SMN1; SMN2 2655/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CHRM2 3040/4885ALDH1A1 481/4885SMN1; SMN2 2118/4885
US-20120190687-A1 Pyrazinylpyrazoles CYP4F3, CYP4B1, CYP1A2 CHRM2 2048/4885ALDH1A1 2140/4885SMN1; SMN2 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.